I like Biosensors for it's recession proof heartstent and it's 2nd generation stents which have been gaining market shares. I have accumulate this company from 23 cts up to over 50 cts. But I have sold all when the chinese company bought over.

I still like this company & recently bought 20 lots.

Only a few people in this forum following / investing in |Biosensors? Me have a small holding, not too convinced about the stock mainly because of my lack of ability to understand the stent business. This is not selling fancy bread or operating aquariums.

The stock has been doing nicely. A market rally does lift a lot of boats. I don't think I will sell yet, as I am sitting on only 15% or so profit, which is also small potatoes given my small holding.

For those who are invested, can you share your views? Trading volume has shot higher but so has many other stocks' trading volume.

1 interesting development is the  issue of S$300m in principal amount of 4.875% fixed rate notes. OCBC analyst highlighted that Biosensors had US$331.7m of net cash as at 30 Sep 2012 -- so it  is not in dire need of money and has sufficient resources for its daily operations
|and working capital.

 Hence the funds raised would likely be used for M&A. Usually, the market likes M^A ... so Biosensors could have a lot of upside  -- already w/o M&A ocbc has  S$1.69 fair value estimate on the stock. BIG will report its 3QFY13 results on 7
Feb post trading hours.
                Maybe I can make a couple more $ to upgrade to  a touchscreen windows 8 laptop!                                                                

Company bought back another 1,496,000 shares today!

Biosensors International Group (BIG) announced that it did a share buyback yesterday. We understand that this is the first ever share buyback done by BIG since its IPO in May 2005. The transaction price was S$1.1127.

Although the amount is relatively small at 1.5m shares (just 0.09% of its total shares outstanding), we believe this sends a positive signal to investors and could set a precedent for future share buybacks.

The share buyback also makes a lot of sense, in our view, given BIG’s large net cash position of US$331.7m (as at 30 Sep 2012). It would also provide BIG with more flexibility as compared to paying out dividends since we believe that BIG is a growth company and would likely reinvest most of its proceeds into growing its business.

Maintain BUY and fair value estimate of S$1.69.

Source: OCBC

This move to commence a share buy back program indicates that the company thinks the stock is  trading at steep discount...

Biosensors has done something to boost confidence of investos. Today, it bought back 1.5 million shares @ ave of $1.1127

CIMB this morning said:

Biosensors’ share price has taken a beating from earnings worries following news of |Terumo’s weak licensing fee to BIG. Management shrugged it off as a 2Q blip and reiterated its strong revenue guidance. 2Q/1HFY13 core net profit was broadly in line, at 23%/46% of our full-year forecasts and 20%/39% of consensus numbers.

|Nevertheless, we cut FY3/13 earnings and our SOP target price to reflect the risk of |weaker licensing income from Japan and potential price cuts in various countries.|This does not affect our Outperform call as product profitability remains strong and valuations are really palatable now. Tgt. S$1.79

It's alredi 1.155. I bought at 1.04 after your call. It can go above 1.23, which is the support level for the past few mths. Thanks Trader for the call. Good luck to you and all.  

haha! i told you.... was $1.055, now $1.135

This counter sure down again,,,,,,,,

die now,, hold too much

Some funds are selling for a reason that has been around quite a while, so it's not new, and it's  mandatory stent price cuts directed by authorities in Japan,  India & China.

Yes you can see how things have hit Terumo Corp (Terumo), which licenses BIG’s drug-eluting stent technology in exchange for a royalty fee.

In results on Tuesday,  you can see its  drug eluting stent sales in Japan was felled by the National Health Insurance’s  official price cut (~15%) and increased competition from new product launches.

Incredible value at now $1.055

Worth at least a small bet at this price level of 1.115.
Strong potential ahead.

Biosensors potential takeover target.

Biosensors continues to be greatly undervalued despite going up 1.5 cents to $1.25 currently. Good luck ,,

Nosges Bank bought 1.379m Biosensors share at $1.26 and increase holding from 4.96% to 5.04%.

Excerpts from DBS Vickers' 14-page report on Singapore Strategy dated 17 Aug 2012.....

Biosensors remains a steal for a company with 30% earnings growth and strong competitive advantage.

Biosensors today touch 1.28.

Watch out Cordlife - profitable medical stock is sure winner. 

Cordlife biz is about saving life. Compare to Insurance the insurance company will pay out if there is a claim but Cordlife will have more biz if there is a need for the cord blood. Cordlife generated net margins of 33%. Our Govt. also provide subsidies. See Cordlife price plan. http://www.cordlife.com/sg/en/price-plan